Ovarian cancer drug study pulled before it began
NCT ID NCT07060365
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 33 times
Summary
This study aimed to test new anticancer drugs, chosen based on specific biomarkers, for people with advanced or recurrent ovarian cancer. It was designed to check safety and early effectiveness, but was withdrawn before enrolling any participants. No results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/RECURRENT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Barcelona, 08028, Spain
Conditions
Explore the condition pages connected to this study.